Literature DB >> 7693974

Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV.

M J Koziel1, D Dudley, N Afdhal, Q L Choo, M Houghton, R Ralston, B D Walker.   

Abstract

Hepatitis C virus (HCV) is a major cause of posttransfusion and community-acquired hepatitis, and a majority of individuals infected with this virus will subsequently develop chronic hepatitis. Characterization of the host immune response to this infection is an important first step that should facilitate the development of immunomodulatory agents and vaccines. Cellular immune responses, especially those mediated by cytotoxic T lymphocytes (CTL), are important in the control of many viral diseases. In this study, liver-infiltrating lymphocytes from persons with chronic HCV hepatitis were examined for evidence of HCV-specific CTL by using target cells infected with recombinant vaccinia viruses expressing the HCV core, E1, E2, and part of the NS2 proteins. Bulk expansion of liver-derived CD8+ lymphocytes resulted in the detection of HCV-specific CTL activity, whereas activity could not be found in CD8+ lymphocytes expanded from peripheral blood. Epitopes recognized by these CTL were defined by using CTL clones obtained by limiting dilution and target cells sensitized with synthetic HCV peptides. Four distinct HLA class I-restricted epitopes were identified, including two epitopes in the amino-terminal portion of the core protein. These studies provide evidence that the highly conserved core protein is a target for HCV-specific CTL and identify CTL epitopes within the more highly variable E2 envelope protein. Our studies also suggest that HCV-specific CTL are localized at the site of tissue injury in infected persons with chronic hepatitis. Identification of the epitopes recognized by HCV-specific CTL will facilitate exploration of their role in disease pathogenesis and may provide information useful in development of therapeutic interventions or vaccines.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693974      PMCID: PMC238218     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  74 in total

Review 1.  Immunology and the liver.

Authors:  M Peters; J Vierling; M E Gershwin; D Milich; F V Chisari; J H Hoofnagle
Journal:  Hepatology       Date:  1991-05       Impact factor: 17.425

2.  Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 A resolution.

Authors:  M A Saper; P J Bjorkman; D C Wiley
Journal:  J Mol Biol       Date:  1991-05-20       Impact factor: 5.469

3.  Antibodies to hepatitis C virus in community-acquired acute non-A, non-B hepatitis.

Authors:  F Bortolotti; A Tagger; P Cadrobbi; C Crivellaro; F Pregliasco; M L Ribero; A Alberti
Journal:  J Hepatol       Date:  1991-03       Impact factor: 25.083

4.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules.

Authors:  K Falk; O Rötzschke; S Stevanović; G Jung; H G Rammensee
Journal:  Nature       Date:  1991-05-23       Impact factor: 49.962

5.  A long-term study of hepatitis C virus replication in non-A, non-B hepatitis.

Authors:  P Farci; H J Alter; D Wong; R H Miller; J W Shih; B Jett; R H Purcell
Journal:  N Engl J Med       Date:  1991-07-11       Impact factor: 91.245

6.  Six epitopes reacting with human cytotoxic CD8+ T cells in the central region of the HIV-1 NEF protein.

Authors:  B Culmann; E Gomard; M P Kiény; B Guy; F Dreyfus; A G Saimot; D Sereni; D Sicard; J P Lévy
Journal:  J Immunol       Date:  1991-03-01       Impact factor: 5.422

7.  Nucleotide sequence and mutation rate of the H strain of hepatitis C virus.

Authors:  N Ogata; H J Alter; R H Miller; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

8.  Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins.

Authors:  A J Weiner; M J Brauer; J Rosenblatt; K H Richman; J Tung; K Crawford; F Bonino; G Saracco; Q L Choo; M Houghton
Journal:  Virology       Date:  1991-02       Impact factor: 3.616

9.  Structure and organization of the hepatitis C virus genome isolated from human carriers.

Authors:  A Takamizawa; C Mori; I Fuke; S Manabe; S Murakami; J Fujita; E Onishi; T Andoh; I Yoshida; H Okayama
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

10.  Genetic organization and diversity of the hepatitis C virus.

Authors:  Q L Choo; K H Richman; J H Han; K Berger; C Lee; C Dong; C Gallegos; D Coit; R Medina-Selby; P J Barr
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

View more
  71 in total

Review 1.  Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B.

Authors:  F V Chisari
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

Review 2.  Immunopathogenesis of viral hepatitis.

Authors:  M U Mondelli
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

3.  Identification of the epitopes on HCV core protein recognized by HLA-A2 restricted cytotoxic T lymphocytes.

Authors:  H C Zhou; D Z Xu; X P Wang; J X Zhang; Y Huang; Y P Yan; Y Zhu; B Q Jin
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

4.  Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.

Authors:  G Missale; R Bertoni; V Lamonaca; A Valli; M Massari; C Mori; M G Rumi; M Houghton; F Fiaccadori; C Ferrari
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

Review 5.  Acute hepatitis C virus infection: a chronic problem.

Authors:  Jason T Blackard; M Tarek Shata; Norah J Shire; Kenneth E Sherman
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

6.  Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy.

Authors:  Curtis Cooper; Stephan Shafran; Susan Greenbloom; Robert Enns; John Farley; Nir Hilzenrat; Kurt Williams; Magdy Elkashab; Nabil Abadir; Manuela Neuman
Journal:  Can J Gastroenterol Hepatol       Date:  2013-11-08

7.  Prominent proliferative response of peripheral blood mononuclear cells to a recombinant non-structural (NS3) protein of hepatitis C virus in patients with chronic hepatitis C.

Authors:  P M Yang; L H Hwang; M Y Lai; W L Huang; Y D Chu; W K Chi; B L Chiang; J H Kao; P J Chen; D S Chen
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

8.  HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release.

Authors:  M J Koziel; D Dudley; N Afdhal; A Grakoui; C M Rice; Q L Choo; M Houghton; B D Walker
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

9.  Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant.

Authors:  A Weiner; A L Erickson; J Kansopon; K Crawford; E Muchmore; A L Hughes; M Houghton; C M Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

Review 10.  Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection.

Authors:  Christoph Neumann-Haefelin; Hans-Christian Spangenberg; Hubert-E Blum; Robert Thimme
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.